梁红宝,李蕊,姚景春,秦国飞,张浩,张贵民
LIANG Hong-bao,LI Rui,YAO Jing-chun,QIN Guo-fei,ZHANG Hao,ZHANG Gui-min

• 1:鲁南制药集团股份有限公司中药制药共性技术国家重点实验室
• 2:山东新时代药业有限公司

摘要(Abstract)：

基于网络药理学和分子对接方法探索首荟通便胶囊治疗便秘的作用机制。利用中药系统药理学分析平台(TCMSP)和中药分子机制的生物信息学分析工具(BATMAN),根据口服利用度(OB)≥30%、类药性(DL)≥0.18的筛选原则获取首荟通便胶囊中8味药材的化学成分和作用靶点;通过GeneCards,PharmGkb等数据库获取便秘相关靶点,药物靶点与疾病靶点取交集得到首荟通便胶囊治疗便秘的潜在作用靶点;采用STRING平台构建潜在靶点蛋白质相互作用(PPI)网络并获得GO分析及KEGG通路数据,进行富集分析预测其作用机制。运用Cytoscape 3.6.1软件构建"药材-化学成分-药物靶点"网络并对PPI网络进行网络拓扑分析。分子对接方法用以验证网络药理学分析首荟通便胶囊治疗便秘结果的准确性。PPI网络分析结果显示有槲皮素、豆甾醇、芦荟大黄素、大黄酸等92个化学成分,关键靶点有AKT1,MAPK1,IL6,JUN,TNF,TP53等。富集分析筛选出157条信号通路(P<0.01),主要涉及白细胞介素17信号通路、糖尿病并发症中的AGE-RAGE信号通路、甲状腺激素信号通路等;分子对接结果显示,度值排名前3的槲皮素、白藜芦醇和赖氨酸对接关键靶点的蛋白结晶复合物构象合理。该研究初步表明,首荟通便胶囊中多种活性成分通过作用于AKT1,MAPK1,IL6,JUN等关键靶点,调节多条信号通路,增加肠道的滑润度和蠕动功能,保证肠道管腔通畅,发挥治疗便秘的作用。
To explore the mechanism of Shouhui Tongbian Capsules in treating constipation by means of network pharmacology and molecular docking approach. Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP) and Bioinfoematics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine(BATMAN) were applied to obtain chemical components and potential targets of eight herbs in Shouhui Tongbian Capsules according to the screening principles of oral availability(OB)≥30% and drug-like property(DL)≥0.18. Disease targets relating to constipation were screened out through GeneCards, PharmGkb and other databases, drug targets were integrated with disease targets, and intersection targets were exactly the potential action targets of Shouhui Tongbian Capsules for treating constipation; PPI network of potential targets was constructed using STRING platform, and GO(gene ontology) analysis and KEGG(Kyoto encyclopedia of genes and genomes) pathway data were obtained to conduct enrichment analysis and predict its mechanism of action. Cytoscape 3.6.1 was used to construct a network of "medicinal materials-chemical components-drug targets", and the network topology analysis was carried out on the PPI network to obtain its main components and key targets. Molecular docking between components and key targets of Shouhui Tongbian Capsules verified the accuracy of network pharmacological analysis results. The PPI network analysis showed 92 chemical components, including quercetin, stigmaste-rol, aloe-emodin, rhein, and key targets for instance AKT1, MAPK1, IL6, JUN, TNF and TP53. The enrichment analysis of KEGG screened out 157 signal pathways(P<0.01), mainly involving interleukin 17 signaling pathway, AGE-RAGE signaling pathway in diabetic complications, thyroid hormone signaling pathway. Quercetin, resveratrol and lysine with top degree value had a rational conformation in docking site of protein crystal complexes. This study preliminarily showed that various active ingredients in Shouhui Tongbian Capsules could regulate multiple signaling pathways, increase intestinal smoothness and peristalsis function, ensure smooth intestinal lumen, and play a role in treating constipation by acting on key targets, such as AKT1, MAPK1, IL6 and JUN.

关键词(KeyWords)： 首荟通便胶囊;便秘;网络药理学;分子对接;GO分析;KEGG通路分析
Shouhui Tongbian Capsules;constipation;network pharmacology;molecular docking;GO analysis;KEGG pathway analysis

Abstract:

Keywords:

基金项目(Foundation): 国家“重大新药创制”科技重大专项(2018ZX09201010)

作者(Author): 梁红宝,李蕊,姚景春,秦国飞,张浩,张贵民
LIANG Hong-bao,LI Rui,YAO Jing-chun,QIN Guo-fei,ZHANG Hao,ZHANG Gui-min

参考文献(References)：

• [1] 资昌艳,陈诚,丁吉林,等.功能性便秘中医研究进展[J].实用中医药杂志,2018,34(10):1277.
• [2] 焦晨莉,张敏,高玉芳,等.当归芦荟胶囊治疗老年功能性便秘临床研究[J].现代中医药,2018,38(5):72.
• [3] 周青,陈玉根.慢性功能性便秘临床治疗研究现状[J].中国中西医结合消化杂志,2013,21(11):611.
• [4] 张海鹏.便秘病证的古今文献研究与学术源流探讨[D].北京:北京中医药大学,2008.
• [5] 杨新庆.慢性便秘研究的回顾[C].杭州:中国中西医结合学会大肠肛门病专业委员会第八届全国学术会议,2001.
• [6] 庞作鹏.136例慢性便秘病例证治规律回顾性分析[D].大连:辽宁中医药大学,2017.
• [7] 刘汶,张声生,李乾构.慢性功能性便秘研究进展[J].中国中西医结合消化杂志,2003,11(6):382.
• [8] 王佩佩,罗雯,禹铮,等.慢性便秘的研究进展[J].中国全科医学,2017,20(3):370.
• [9] 叶飞,王巧民.慢性便秘的流行病学研究进展[J].中国临床保健杂志,2010,13(6):665.
• [10] 赵劢,谭至柔.成年人慢性便秘流行病学的研究现状[J].世界华人消化杂志,2014,22(7):939.
• [11] 方秀才,鲁素彩,潘国宗,等.北京地区成年非病人人群排便的流行病学调查[J].中华医学杂志,2001,81(21):1287.
• [12] LEMBO A,CAMILLERI M.Chronic constipation[J].N Engl J Med,2003,349(14):1360.
• [13] 黄小明,张敏.肠道菌群与慢性便秘关系的研究进展[J].安徽医药,2020,24(2):220.
• [14] 陈品侠.慢性便秘的诊断和治疗进展[J].安徽医学,2012,33(8):1104.
• [15] 竺翊,余苏萍.功能性便秘中西医治疗进展[J].辽宁中医学院学报,2014,16(4):223.
• [16] 贡鸣,李岩.功能性便秘的治疗现状[J].中国当代医药,2009,16(16):199.
• [17] 赵威,柯美云.功能性便秘[J].医学与哲学,2008,29(12):15.
• [18] 张秋瓒,杨华.功能性便秘的药物治疗[J].中国全科医学,2005,8(2):129.
• [19] 丁晓洁,董正平,孙喜灵.《中药成方制剂》治疗便秘方剂的组方规律与优势病证分析[J].时珍国医国药,2018,29(2):476.
• [20] 刘蔚雯.《金匮要略》枳术汤及类方治痞探析[J].中国中医急症,2009,18(4):606.
• [21] 中华医学会消化病学分会胃肠动力学组,功能性胃肠病协作组.中国慢性便秘专家共识意见(2019,广州) [J].中华消化杂志,2019,39(9):577.
• [22] 周佳宝,周锦花.首荟通便胶囊治疗老年功能性便秘的疗效观察[J].中国全科医学,2019,22(S2):149.
• [23] 董培良,李慧,韩华.中药网络药理学的应用与思考[J].中国实验方剂学杂志,2020,26(17):204.
• [24] 刘嘉辉,吕东勇,周厚明,等.基于网络药理学和分子对接研究龙葵治疗肝癌的分子机制[J].中国中药杂志,2020,45(1):163.
• [25] 邓芳芳.药物分子的计算机辅助理论模拟及分子设计[D].兰州:兰州大学,2014.
• [26] 刘吉元.蛋白质与配体相互作用分子模拟研究[D].杨凌:西北农林科技大学,2014.
• [27] 赵苗青,李丰,石彬彬,等.系统药理学(Ⅵ)——TCMSP数据库及其应用[J].中医药信息,2020,37(3):22.
• [28] RU J L,LI P,WANG J N,et al.TCMSP:a database of systems pharmacology for drug discovery from herbal medicines[J].J Cheminformatics,2014,6(1):13.
• [29] 段凯旋,罗文浩,罗琼,等.基于BATMAN-TCM在线分析平台研究钩藤药理机制[J].井冈山大学学报(自然科学版),2019,40(2):91.
• [30] LIU Z Y,GUO F F,WANG Y,et al.BATMAN-TCM:a bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine[J].Sci Rep,2016,doi:10.1038/srep21146.
• [31] 陈铭泰,肖娇,林海丹,等.基于网络药理学探讨逍遥散对动脉粥样硬化和抑郁症“异病同治”的作用机制[J].中国中药杂志,2020,45(17):4099.
• [32] 杨婷,陈利娜,瞿水清,等.基于网络药理学的生脉饮(党参方)治疗动脉粥样硬化性心血管疾病的潜在分子机制[J].中国实验方剂学杂志,2020,26(17):151.
• [33] SOMERS W,STAHL M,SEEHRA J S.1.9 A crystal structure of interleukin 6:implications for a novel mode of receptor dimeri-zation and signaling[J].EMBO J,1997,16(5):989.
• [34] 韩洁,王俊平,张姣兰,等.首荟通便胶囊治疗功能性便秘的临床观察[C].济南:第三十一届全国中西医结合消化系统疾病学术会议,2019.
• [35] 张树彬,刘炫廷,张贞喜,等,首荟通便胶囊预防肝胆胰恶性肿瘤化疗后便秘的疗效观察[J].世界中医药,2020,15(5):764.
• [36] 高春会,梁平,史淑萍,等.首荟通便胶囊预防肿瘤化疗所致便秘的临床观察[J].中国老年保健医学,2019,17(4):86.